1bzv
From Proteopedia
(New page: 200px<br /><applet load="1bzv" size="450" color="white" frame="true" align="right" spinBox="true" caption="1bzv" /> '''[D-ALAB26]-DES(B27-B30)-INSULIN-B26-AMIDE A ...) |
|||
| Line 1: | Line 1: | ||
| - | [[Image:1bzv.gif|left|200px]]<br /><applet load="1bzv" size=" | + | [[Image:1bzv.gif|left|200px]]<br /><applet load="1bzv" size="350" color="white" frame="true" align="right" spinBox="true" |
caption="1bzv" /> | caption="1bzv" /> | ||
'''[D-ALAB26]-DES(B27-B30)-INSULIN-B26-AMIDE A SUPERPOTENT SINGLE-REPLACEMENT INSULIN ANALOGUE, NMR, MINIMIZED AVERAGE STRUCTURE'''<br /> | '''[D-ALAB26]-DES(B27-B30)-INSULIN-B26-AMIDE A SUPERPOTENT SINGLE-REPLACEMENT INSULIN ANALOGUE, NMR, MINIMIZED AVERAGE STRUCTURE'''<br /> | ||
==Overview== | ==Overview== | ||
| - | This paper reports on an insulin analogue with 12.5-fold receptor | + | This paper reports on an insulin analogue with 12.5-fold receptor affinity, the highest increase observed for a single replacement, and on its solution structure, determined by NMR spectroscopy. The analogue is [D-AlaB26]des-(B27-B30)-tetrapeptide-insulin-B26-amide. C-terminal truncation of the B-chain by four (or five) residues is known not to affect the functional properties of insulin, provided the new carboxylate charge is neutralized. As opposed to the dramatic increase in receptor affinity caused by the substitution of D-Ala for the wild-type residue TyrB26 in the truncated molecule, this very substitution reduces it to only 18% of that of the wild-type hormone when the B-chain is present in full length. The insulin molecule in solution is visualized as an ensemble of conformers interrelated by a dynamic equilibrium. The question is whether the "active" conformation of the hormone, sought after in innumerable structure/function studies, is or is not included in the accessible conformational space, so that it could be adopted also in the absence of the receptor. If there were any chance for the active conformation, or at least a predisposed state to be populated to a detectable extent, this chance should be best in the case of a superpotent analogue. This was the motivation for the determination of the three-dimensional structure of [D-AlaB26]des-(B27-B30)-tetrapeptide-insulin-B26-amide. However, neither the NMR data nor CD spectroscopic comparison of a number of related analogues provided a clue concerning structural features predisposing insulin to high receptor affinity. After the present study it seems more likely than before that insulin will adopt its active conformation only when exposed to the force field of the receptor surface. |
==About this Structure== | ==About this Structure== | ||
| - | 1BZV is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http:// | + | 1BZV is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1BZV OCA]. |
==Reference== | ==Reference== | ||
| Line 14: | Line 14: | ||
[[Category: Synthetic construct]] | [[Category: Synthetic construct]] | ||
[[Category: Brandenburg, D.]] | [[Category: Brandenburg, D.]] | ||
| - | [[Category: Gattner, H | + | [[Category: Gattner, H G.]] |
[[Category: Grotzinger, J.]] | [[Category: Grotzinger, J.]] | ||
[[Category: Hagelstein, M.]] | [[Category: Hagelstein, M.]] | ||
| Line 24: | Line 24: | ||
[[Category: superpotency]] | [[Category: superpotency]] | ||
| - | ''Page seeded by [http:// | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 12:00:55 2008'' |
Revision as of 10:00, 21 February 2008
|
[D-ALAB26]-DES(B27-B30)-INSULIN-B26-AMIDE A SUPERPOTENT SINGLE-REPLACEMENT INSULIN ANALOGUE, NMR, MINIMIZED AVERAGE STRUCTURE
Overview
This paper reports on an insulin analogue with 12.5-fold receptor affinity, the highest increase observed for a single replacement, and on its solution structure, determined by NMR spectroscopy. The analogue is [D-AlaB26]des-(B27-B30)-tetrapeptide-insulin-B26-amide. C-terminal truncation of the B-chain by four (or five) residues is known not to affect the functional properties of insulin, provided the new carboxylate charge is neutralized. As opposed to the dramatic increase in receptor affinity caused by the substitution of D-Ala for the wild-type residue TyrB26 in the truncated molecule, this very substitution reduces it to only 18% of that of the wild-type hormone when the B-chain is present in full length. The insulin molecule in solution is visualized as an ensemble of conformers interrelated by a dynamic equilibrium. The question is whether the "active" conformation of the hormone, sought after in innumerable structure/function studies, is or is not included in the accessible conformational space, so that it could be adopted also in the absence of the receptor. If there were any chance for the active conformation, or at least a predisposed state to be populated to a detectable extent, this chance should be best in the case of a superpotent analogue. This was the motivation for the determination of the three-dimensional structure of [D-AlaB26]des-(B27-B30)-tetrapeptide-insulin-B26-amide. However, neither the NMR data nor CD spectroscopic comparison of a number of related analogues provided a clue concerning structural features predisposing insulin to high receptor affinity. After the present study it seems more likely than before that insulin will adopt its active conformation only when exposed to the force field of the receptor surface.
About this Structure
1BZV is a Protein complex structure of sequences from Synthetic construct. Full crystallographic information is available from OCA.
Reference
The solution structure of a superpotent B-chain-shortened single-replacement insulin analogue., Kurapkat G, Siedentop M, Gattner HG, Hagelstein M, Brandenburg D, Grotzinger J, Wollmer A, Protein Sci. 1999 Mar;8(3):499-508. PMID:10091652
Page seeded by OCA on Thu Feb 21 12:00:55 2008
